Accelerating the New
Glaucoma Paradigm
Accelerating the New
Glaucoma Paradigm
Unlock first-line glaucoma care with Voyager™ DSLT
Consistent, precise treatment at the touch of a button.1
Hydrus® Microstent
The first and only MIGS device to report significant safety and effectiveness outcomes from a pivotal trial at 5 years.2,3
1. Voyager DSLT User Guide (US). [REF-26202].
2. Ahmed IIK, et al. Long-term outcomes from the HORIZON randomized trial for Schlemm’s Canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129(7):742-751.
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients. ClinTrials.gov (NCT01539239).
©2025 Alcon Inc. 01/25 US-DLT-2500017
